The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Gideon Hirschfield, PhD, MB BChir, Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the University of Toronto, sat down with HCPLive Hepatology to discuss the role of the microbiome in autoimmune liver disease.
Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.
A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.
Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.
Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.
Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.